Dual Incretin Mimetic (GLP-1 & GIP Agonist) | Metabolic & Obesity Research Peptide | For Research Use Only

Tirzepatide is a cutting-edge dual peptide agonist targeting GLP-1 and GIP receptors, designed to mimic the natural incretin response and enhance metabolic function. Its ability to reduce appetite, improve insulin sensitivity, and stimulate fat loss has made it one of the most promising compounds in obesity and type 2 diabetes research.

This 10mg format is ideal for low-dose or early-phase studies exploring safety, response curves, or combination protocols.

🔍 Key Features

• Dual Agonist: GLP-1 and GIP Receptors

• Supports Appetite Regulation & Satiety

• Improves Glycaemic Control & Insulin Response

• Promotes Fat Reduction & Body Composition Improvement

• Ideal for Weekly Dosing Models in Research

• Well-Tolerated & Long-Lasting Effects

⚙️ Compound Details

• Peptide Name: Tirzepatide

• CAS Number: 2023788-19-2

• Molecular Formula: C₂₂₅H₃₄₀N₆₀O₆₅

• Molecular Weight: ~4813.45 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 10mg per vial

🧊 Storage & Handling

• Storage (lyophilised): –20°C in a cool, dry, and dark location

• Reconstitution: Add 1–2ml sterile bacteriostatic water

• Post-Reconstitution: Store between 2–8°C and use within 10–14 days

• Avoid: Direct heat, sunlight, and freeze-thaw cycles

⚠️ For Research Use Only

Tirzepatide – 10mg is supplied exclusively for laboratory research purposes. It is not intended for human consumption, medical, or diagnostic use.